Angiotensin-Converting Enzyme Inhibitors Reduce Uterine Fibroid Incidence in Hypertensive Women.

Like Comment
In-vitro and in-vivo evidence has supported the role of angiotensin II blockade in reducing leiomyoma cell proliferation and growth. However, no population-based study to date has investigated this potential association.To determine if prior Angiotensin-Converting Enzyme inhibitor (ACEi) use is associated with reduced odds of leiomyoma development.A nested case-control study.The population was assembled from the Truven Health Marketscan® Research Database, which includes private health insurance claims from January 1 st, 2012 to December 31 st, 2017.We included (n=353,917) women aged 18-65 with hypertension. Cases (n=13,108) with a leiomyoma diagnosis were matched to controls (n=340,808) with no such diagnosis at a 1:26 ratio by age and region of origin within the United States.Prior use of ACEi was determined from outpatient drug claims.Leiomyoma development was indicated by a first time diagnosis code.Women on an ACEi experienced a 31.8% reduced odds of developing clinically recognized leiomyoma compared to non-users (OR 0.68, 95% CI 0.65-0.72). This association was significant for each age group: 30-39 (OR 0.86, 95% CI 0.74-0.99), 40-49 (OR 0.71, 95% CI 0.66-0.76), 50-59 (OR 0.63, 95% CI 0.58-0.69) and 60-65 years old (OR 0.58, 95% CI 0.50-0.69). Of the ACEi's, Lisinopril (OR 0.67, 95% CI 0.64-0.71), Quinapril (OR 0.62, 95% CI 0.41-0.92) and Ramipril (OR 0.35, 95% CI 0.23-0.50) demonstrated a significant association with reduced leiomyoma incidence.ACEi use is associated with reduced odds of developing clinically recognized leiomyoma in adult hypertensive women.


View the article @ The Journal of clinical endocrinology and metabolism


Get PDF with LibKey

ClinOwl

The wider, wiser view for healthcare professionals. ClinOwl signposts the latest clinical content from over 100 leading medical journals.
3373 Contributions
1 Followers
0 Following

No comments yet.